Org: Centre Léon Bérard, School of Medicine, Showa University, Centre François Baclesse, Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Claudius Regaud, IUCT-Oncopole, CRCT, lnserm, Toulouse, France,

Abstract

Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

Org: University of Chicago Department of Surgery, University of Chicago Medical Center, Chicago, IL, Department of Medicine, University of Chicago, Department of Radiation and Cellular Oncology, Rush University Medical Center,

Abstract

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,

Abstract

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.

Org: West German Cancer Center, University Hospital Essen, Jessa Hospital, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Pathology and Neuropathology,

Abstract

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.

Org: University of Leicester and Leicester University Hospitals, University of Southampton, Harry Perkins Institute of Medical Research, Perth, Australia, Liverpool, United Kingdom,

Abstract

Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).

Org: Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, UCL Cancer Center, University College London, London, United Kingdom, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan,

Abstract

Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.

Org: Netherlands Cancer Institute (NKI-AVL), Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, The Netherlands Cancer Institute, University Medical Cancer Center Utrecht, Netherlands Cancer Institute,

Clinical trial

A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2021-09-28

Clinical trial

A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma

Status: Completed, Estimated PCD: 2018-11-01

Clinical trial

A Phase 1b Trial in Stage II-III Urothelial Cancer to Explore Pre-operative Immunotherapy

Status: Active (not recruiting), Estimated PCD: 2023-06-02

Clinical trial

Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study

Status: Completed, Estimated PCD: 2023-09-15

Clinical trial

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.

Status: Active (not recruiting), Estimated PCD: 2022-10-14

Clinical trial

A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Status: Completed, Estimated PCD: 2020-11-20

Clinical trial

A Phase II Study of Fedratinib and Nivolumab Combination in Patients With Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Proof-of-Concept Multicenter Trial Evaluating Response Adapted Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Pilot Study of Nivolumab in Combination With Therasphere (Yttrium-90) for Treatment of Hepatocellular Carcinoma (HCC) With Intent for Resection

Status: Terminated, Estimated PCD: 2023-10-19

Clinical trial

Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated With the Combination of Sorafenib Plus Nivolumab as First-Line of Systemic Therapy

Status: Active (not recruiting), Estimated PCD: 2023-11-30

Clinical trial

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127

Status: Active (not recruiting), Estimated PCD: 2023-09-25

Clinical trial

A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and Ipilimumab

Status: Active (not recruiting), Estimated PCD: 2024-09-13

Clinical trial

A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-20

Clinical trial

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal Mesothelioma

Status: Completed, Estimated PCD: 2023-04-13

Clinical trial

A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma

Status: Completed, Estimated PCD: 2024-02-20

Clinical trial

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Status: Completed, Estimated PCD: 2023-01-26

Clinical trial

HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Status: Recruiting, Estimated PCD: 2026-03-31

Clinical trial

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors

Status: Terminated, Estimated PCD: 2021-11-24

Clinical trial

Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Status: Completed, Estimated PCD: 2022-02-14

Clinical trial

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Phase II Study From the POLA National Network of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas

Status: Completed, Estimated PCD: 2020-12-02

Clinical trial

Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder Tumors

Status: Not yet recruiting, Estimated PCD: 2024-07-01

Clinical trial

Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-08-08

Clinical trial

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland

Status: Active (not recruiting), Estimated PCD: 2021-02-24

Clinical trial

Window-of-Opportunity Trial of Nivolumab and BMS986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (CA017-087)

Status: Active (not recruiting), Estimated PCD: 2025-12-01

Clinical trial

A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Clinical trial

A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus

Status: Active (not recruiting), Estimated PCD: 2018-09-20

Clinical trial

Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Status: Not yet recruiting, Estimated PCD: 2028-09-30

Clinical trial

A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-Cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Recruiting, Estimated PCD: 2027-06-28

Clinical trial

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Status: Recruiting, Estimated PCD: 2027-12-31

Clinical trial

Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma

Status: Completed, Estimated PCD: 2017-11-30

Clinical trial

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2018-10-26

Clinical trial

Safety, Immunogenicity and Efficacy of Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (ART)

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell Carcinoma

Status: Completed, Estimated PCD: 2022-12-02

Clinical trial

A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China

Status: Active (not recruiting), Estimated PCD: 2025-04-28

Clinical trial

An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Status: Recruiting, Estimated PCD: 2028-07-30

Clinical trial

Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Status: Active (not recruiting), Estimated PCD: 2020-01-03

Clinical trial

Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence

Status: Terminated, Estimated PCD: 2023-12-21

Clinical trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition

Status: Completed, Estimated PCD: 2022-08-31

Clinical trial

Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer

Status: Completed, Estimated PCD: 2021-09-01

Clinical trial

Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)

Status: Recruiting, Estimated PCD: 2031-01-01

Clinical trial

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Status: Active (not recruiting), Estimated PCD: 2022-12-22

Clinical trial

A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors

Status: Recruiting, Estimated PCD: 2027-05-31

Clinical trial

A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-06-01

Clinical trial

A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma

Status: Completed, Estimated PCD: 2022-03-04

Clinical trial

Phase II Maintenance Trial of Nivolumab for Newly Diagnosed PCNSL Patients With Persistent Circulating Tumor DNA in the CSF After Completion of Methotrexate-Based First-Line Induction Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2026-05-22

Clinical trial

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Status: Active (not recruiting), Estimated PCD: 2021-09-09

Clinical trial

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial

Status: Not yet recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2027-09-30

Clinical trial

A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Status: Recruiting, Estimated PCD: 2025-05-03

Clinical trial

A Phase 2 Study of Palliative Radiation and Combination Sequential Immunotherapy for Metastatic Cutaneous Melanoma and Ocular Melanoma

Status: Completed, Estimated PCD: 2021-05-04

Clinical trial

A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers

Status: Recruiting, Estimated PCD: 2027-01-31

Clinical trial

Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma

Status: Active (not recruiting), Estimated PCD: 2025-10-31

Clinical trial

A Phase I Study of Pomalidomide and Nivolumab in Patients With Virus-Associated Malignancies With or Without HIV

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL

Status: Completed, Estimated PCD: 2020-10-30

Clinical trial

GU-187: Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2024-11-28

Clinical trial

A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced Melanoma

Status: Active (not recruiting), Estimated PCD: 2022-12-27

Clinical trial

A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

Phase 2 Study of Nivolumab Plus Lenvatinib for Patients With Unresectable Anaplastic Thyroid Cancer (NAVIGATION Study)

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Status: Recruiting, Estimated PCD: 2026-04-11

Clinical trial

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk Melanoma

Status: Recruiting, Estimated PCD: 2027-02-15

Clinical trial

Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)

Status: Completed, Estimated PCD: 2023-10-17

Clinical trial

Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Status: , Estimated PCD: 2026-01-31

Clinical trial

Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma

Status: Active (not recruiting), Estimated PCD: 2024-04-24

Clinical trial

Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2022-11-18

Clinical trial

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

Status: Active (not recruiting), Estimated PCD: 2024-10-31

Clinical trial

LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma

Status: Recruiting, Estimated PCD: 2025-10-30

Clinical trial

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-01-31

Clinical trial

A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.

Status: Active (not recruiting), Estimated PCD: 2030-04-01

Clinical trial

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Status: Active (not recruiting), Estimated PCD: 2025-07-31

Clinical trial

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

Status: Recruiting, Estimated PCD: 2027-03-01

Clinical trial

Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer

Status: Completed, Estimated PCD: 2020-10-06

Clinical trial

Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain Metastases

Status: Active (not recruiting), Estimated PCD: 2027-01-01

Clinical trial

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Status: Active (not recruiting), Estimated PCD: 2023-07-01

Clinical trial

A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

Status: Active (not recruiting), Estimated PCD: 2025-02-15

Clinical trial

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

SCANDIUM II Trial - A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases

Status: Active (not recruiting), Estimated PCD: 2024-08-04

Clinical trial

Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In

Status: Withdrawn, Estimated PCD: 2029-12-29

Clinical trial

Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment

Status: Completed, Estimated PCD: 2021-07-28

Clinical trial

A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2021-01-30

Clinical trial

A Phase II Open-Label, Single Centre, Non-Randomised Trial Of Y90-Radioembolization In Combination With Nivolumab In Asian Patients With Advanced Hepatocellular Carcinoma

Status: Active (not recruiting), Estimated PCD: 2019-08-31

Clinical trial

Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Status: Recruiting, Estimated PCD: 2024-05-01

Clinical trial

Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299

Status: Terminated, Estimated PCD: 2022-05-11

Clinical trial

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Status: Recruiting, Estimated PCD: 2026-04-30

Clinical trial

PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse

Status: Completed, Estimated PCD: 2023-08-08

Clinical trial

A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Status: Recruiting, Estimated PCD: 2023-10-17

Clinical trial

Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers

Status: Active (not recruiting), Estimated PCD: 2026-03-01

Clinical trial

Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab

Status: Active (not recruiting), Estimated PCD: 2024-02-23

Clinical trial

Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab in Stage IIIB/C/D Melanoma Patients With an Integrated Imaging Biomarker

Status: Active (not recruiting), Estimated PCD: 2028-07-30

Clinical trial

Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2020-09-21

Clinical trial

A Phase 1 Study of Combination Nivolumab and Ipilimumab With Irradiated GM-CSF Secreting Autologous Neuroblastoma Cell Vaccine (GVAX) for Relapsed or Refractory Neuroblastoma

Status: Active (not recruiting), Estimated PCD: 2027-01-01

Clinical trial

A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Status: Completed, Estimated PCD: 2023-10-24

Clinical trial

A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC

Status: Recruiting, Estimated PCD: 2026-04-28

Clinical trial

Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2026-06-30

Clinical trial

An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2021-04-22

Clinical trial

Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors

Status: Active (not recruiting), Estimated PCD: 2024-02-21

Clinical trial

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Status: Active (not recruiting), Estimated PCD: 2025-01-31

Clinical trial

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Status: Completed, Estimated PCD: 2019-11-01

Clinical trial

Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer

Status: Completed, Estimated PCD: 2024-04-01

Clinical trial

Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Status: Recruiting, Estimated PCD: 2024-07-26

Clinical trial

MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 Therapy

Status: Withdrawn, Estimated PCD: 2023-01-17

Clinical trial

TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2026-06-22

Clinical trial

Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers

Status: Completed, Estimated PCD: 2022-11-05

Clinical trial

Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081

Status: Active (not recruiting), Estimated PCD: 2024-02-06

Clinical trial

Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung

Status: Not yet recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2025-08-01

Clinical trial

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Status: Active (not recruiting), Estimated PCD: 2025-10-30

Clinical trial

A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Status: Completed, Estimated PCD: 2019-03-27

Clinical trial

A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Status: Active (not recruiting), Estimated PCD: 2021-07-09

Clinical trial

Stereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2024-10-02

Clinical trial

Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma

Status: Active (not recruiting), Estimated PCD: 2028-06-14

Clinical trial

A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)

Status: Active (not recruiting), Estimated PCD: 2025-03-01

Clinical trial

Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Phase 2 Study of Denosumab in Combination With a PD-1 Inhibitor in Subjects With Stage III/IV Melanoma

Status: Completed, Estimated PCD: 2023-04-15

Clinical trial

Neoadjuvant Anti-PD-1 Drug Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial

Status: Completed, Estimated PCD: 2024-03-15

Clinical trial

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-10-25

Clinical trial

A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer

Status: Recruiting, Estimated PCD: 2027-05-31

Clinical trial

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative Cancers

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Nivolumab and Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults

Status: Recruiting, Estimated PCD: 2027-03-01

Clinical trial

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2028-07-05

Clinical trial

Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial

Status: Active (not recruiting), Estimated PCD: 2023-02-01

Clinical trial

Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE

Status: Not yet recruiting, Estimated PCD: 2026-02-01

Clinical trial

UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Status: Terminated, Estimated PCD: 2024-01-31

Clinical trial

Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2023-12-15

Clinical trial

Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer

Status: Recruiting, Estimated PCD: 2027-12-09

Clinical trial

A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Status: Active (not recruiting), Estimated PCD: 2026-12-01

Clinical trial

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Status: Not yet recruiting, Estimated PCD: 2024-10-01

Clinical trial

Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-14

Clinical trial

A Phase II Trial of Sitravatinib Plus Nivolumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma Who Progressed on Prior Treatment Acronym: SNAPI (Sitravatinib and Nivolumab After Prior Immunotherapy)

Status: Active (not recruiting), Estimated PCD: 2025-01-31

Clinical trial

Bevacizumab and Immune chEckpoint Inhibitors Plus Hypofractionated Stereotactic radioTherapy for the Treatment of sympTomatic mElanoma bRain Metastases.

Status: Not yet recruiting, Estimated PCD: 2026-01-30

Clinical trial

Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

Radiation Therapy, Plasma Exchange, and Immunotherapy in Melanoma

Status: Active (not recruiting), Estimated PCD: 2023-11-01

Clinical trial

A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2032-05-05

Clinical trial

Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2029-04-01

Clinical trial

Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2021-09-04

Clinical trial

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

Status: Completed, Estimated PCD: 2019-12-02

Clinical trial

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-04-15

Clinical trial

PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Status: Active (not recruiting), Estimated PCD: 2022-01-11

Clinical trial

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Status: Active (not recruiting), Estimated PCD: 2023-03-31

Clinical trial

A Phase II Trial of Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-04-15

Clinical trial

The GOING Study: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma Progressing Under Sorafenib or After Discontinuation of Atezolizumab Plus Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

MEL-212: A Phase I Proof-of-Concept Study of CBL0137 (Curaxin) Combined With Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma

Status: , Estimated PCD: 2025-03-04

Clinical trial

Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2019-07-02

Clinical trial

Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-08-31

Clinical trial

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Status: Withdrawn, Estimated PCD: 2026-06-01

Clinical trial

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Status: Active (not recruiting), Estimated PCD: 2024-09-23

Clinical trial

Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Status: Recruiting, Estimated PCD: 2026-09-30

Clinical trial

COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Status: Completed, Estimated PCD: 2023-06-20

Clinical trial

Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors

Status: Recruiting, Estimated PCD: 2024-01-20

Clinical trial

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Status: Recruiting, Estimated PCD: 2025-02-28

Clinical trial

Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors

Status: Completed, Estimated PCD: 2020-02-20

Clinical trial

Phase II Trial of Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-Related Oropharynx Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer or Biliary Tract Cancer.

Status: Completed, Estimated PCD: 2022-01-05

Clinical trial

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Status: Terminated, Estimated PCD: 2023-11-20

Clinical trial

PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma

Status: Completed, Estimated PCD: 2022-10-10

Clinical trial

Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Status: Completed, Estimated PCD: 2023-06-12

Clinical trial

A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas

Status: Recruiting, Estimated PCD: 2027-01-01

Clinical trial

Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid Tumors

Status: Completed, Estimated PCD: 2023-12-27

Clinical trial

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Status: Recruiting, Estimated PCD: 2029-06-01

Clinical trial

Immunotherapy in Patients With Early dMMR Rectal Cancer

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 in Advanced Hepatocellular Carcinoma (HCC) Patients

Status: Active (not recruiting), Estimated PCD: 2024-12-13

Clinical trial

The TNT Protocol: A Phase 2 Study Using Talimogene Laherparepvec,Nivolumab and Trabectedin as First, Second/Third Line Therapy for Advanced Sarcoma, Including Desmoid Tumor and Chordoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Status: Completed, Estimated PCD: 2022-10-03

Clinical trial

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial

Status: Completed, Estimated PCD: 2022-02-01

Clinical trial

Phase I Clinical Trial on Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma

Status: , Estimated PCD: 2023-11-17

Clinical trial

A Phase II Trial Evaluating Conformational Intensity Modulated Radiotherapy With Concomitant Nivolumab Followed by Nivolumab for Patients With Locally Advanced Non-small Cell Lung Cancer

Status: Completed, Estimated PCD: 2023-04-15

Clinical trial

Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With Steroids

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Interest of iRECIST Radiological Assessment for Disease Control Rate (DCR) for Evaluation of Patients With Metastatic Colorectal Cancer dMMR and/or MSI Treated With Nivolumab and Ipilimumab. A GERCOR Open-label Phase II Study NIPICOL C17-01

Status: Active (not recruiting), Estimated PCD: 2019-02-21

Clinical trial

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).

Status: , Estimated PCD: 2023-12-01

Clinical trial

Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Status: Recruiting, Estimated PCD: 2025-04-12

Clinical trial

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progressive/Recurrent Meningioma

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial With NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy Squamous Cell Carcinoma of the Head and Neck (SCCHN) - NIVACTOR Study

Status: Completed, Estimated PCD: 2020-03-26

Clinical trial

A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

Status: Completed, Estimated PCD: 2021-01-01

Clinical trial

A Phase II Trial of Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Status: Recruiting, Estimated PCD: 2026-08-31

Clinical trial

A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Status: Terminated, Estimated PCD: 2020-05-29

Clinical trial

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Status: Active (not recruiting), Estimated PCD: 2025-06-01

Clinical trial

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Status: Recruiting, Estimated PCD: 2023-05-31

Clinical trial

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION)

Status: Terminated, Estimated PCD: 2023-01-30

Clinical trial

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

Status: Recruiting, Estimated PCD: 2032-04-30

Clinical trial

Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial

Status: Completed, Estimated PCD: 2021-02-18

Clinical trial

Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-01-26

Clinical trial

Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal Carcinoma

Status: Completed, Estimated PCD: 2021-08-18

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10495

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20180

Abstract

https://www.abstractsonline.com/pp8/#!/20272/presentation/11424

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20466

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20191

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20340

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20263

Abstract

https://www.abstractsonline.com/pp8/#!/20272/presentation/11402

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20274

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20179

Clinical trial

A Prospective Randomized International Multicenter Study to Compare Short Versus Long Adjuvant Immunotherapy After Radical Surgery of Stage IIb-c, III and IV Cutaneous Malignant Melanoma (Grand SLAM)

Status: Not yet recruiting, Estimated PCD: 2030-09-01

Clinical trial

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Status: Completed, Estimated PCD: 2024-05-31

Document

DailyMed Label: OPDIVO

Organization

E.R. Squibb & Sons, L.L.C.